Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-701, a T cell receptors (TCR) based therapy in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma; and CD19, a chimeric antigen receptor T cell therapy for expressing B cell malignancies setting. It has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T cell therapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone832-384-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$190,000.00
Profitability
Miscellaneous
Employees137
OptionableOptionable
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.03. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.07 million. View Bellicum Pharmaceuticals' Earnings History.
When is Bellicum Pharmaceuticals' next earnings date?
What price target have analysts set for BLCM?
3 brokerages have issued twelve-month price targets for Bellicum Pharmaceuticals' shares. Their forecasts range from $6.85 to $19.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $14.6167 in the next year. This suggests a possible upside of 361.1% from the stock's current price. View Analyst Price Targets for Bellicum Pharmaceuticals.
What is the consensus analysts' recommendation for Bellicum Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellicum Pharmaceuticals.
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
Media stories about BLCM stock have trended positive recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Synthorx (THOR), ProQR Therapeutics (PRQR), Arcus Biosciences (RCUS), Prothena (PRTA), BioSpecifics Technologies (BSTC), GlycoMimetics (GLYC), Corbus Pharmaceuticals (CRBP), Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Forty Seven (FTSV), Corium International (CORI), Theratechnologies (THERF), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL) and Clementia Pharmaceuticals (CMTA).
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
- Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
- Mr. Thomas J. Farrell, Consultant (Age 56)
- Mr. Atabak Mokari, Chief Financial Officer (Age 42)
- Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.
Who are Bellicum Pharmaceuticals' major shareholders?
Bellicum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.77%), Geode Capital Management LLC (1.17%), Northern Trust Corp (1.08%), Millennium Management LLC (0.87%), Two Sigma Investments LP (0.43%) and Rhumbline Advisers (0.38%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer, Jon P Stonehouse and Ken Moseley. View Institutional Ownership Trends for Bellicum Pharmaceuticals.
Which institutional investors are selling Bellicum Pharmaceuticals stock?
BLCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Creative Planning, Northern Trust Corp, Virtu Financial LLC and Mcdaniel Terry & Co.. Company insiders that have sold Bellicum Pharmaceuticals company stock in the last year include Alan A Musso and David M Spencer. View Insider Buying and Selling for Bellicum Pharmaceuticals.
Which institutional investors are buying Bellicum Pharmaceuticals stock?
BLCM stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Rhumbline Advisers, Bank of America Corp DE, Geode Capital Management LLC, SG Americas Securities LLC, Two Sigma Advisers LP, Paloma Partners Management Co and Knott David M. Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Jon P Stonehouse. View Insider Buying and Selling for Bellicum Pharmaceuticals.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $3.17.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $137.45 million and generates $190,000.00 in revenue each year. The biopharmaceutical company earns $-91,770,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Bellicum Pharmaceuticals employs 137 workers across the globe.
What is Bellicum Pharmaceuticals' official website?
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
